Search tips
Search criteria 


Logo of mbioJournal InfoAuthorsReviewersBoard of EditorsJournals ASM.orgmBiomBio Article
mBio. 2017 Mar-Apr; 8(2): e02160-16.
Published online 2017 March 14. doi:  10.1128/mBio.02160-16
PMCID: PMC5350470

Arginine Is a Critical Substrate for the Pathogenesis of Pseudomonas aeruginosa in Burn Wound Infections

Vanessa Sperandio, Editor
Vanessa Sperandio, UT Southwestern Medical Center Dallas;


Environmental conditions affect bacterial behavior and can greatly influence the course of an infection. However, the environmental cues that elicit bacterial responses in specific infection sites are relatively unknown. Pseudomonas aeruginosa is ubiquitous in nature and typically innocuous. However, it is also one of the most prevalent causes of fatal sepsis in burn wound patients. The aim of this study was to determine the impact of environmental factors, specifically the availability of arginine, on the pathogenesis of P. aeruginosa in burn wound infections. Comparison of burned versus noninjured tissue revealed that l-arginine (l-Arg) was significantly depleted in burn wounds as a consequence of elevated arginase produced by myeloid-derived suppressor cells. We also observed that l-Arg was a potent chemoattractant for P. aeruginosa, and while low concentrations of l-Arg increased P. aeruginosa’s swimming motility, high concentrations resulted in diminished swimming. Based on these observations, we tested whether the administration of exogenous l-Arg into the burn wound could attenuate the virulence of P. aeruginosa in thermally injured mice. Administration of l-Arg resulted in decreased P. aeruginosa spread and sepsis and increased animal survival. Taken together, these data demonstrate that the availability of environmental arginine greatly influences the virulence of P. aeruginosa in vivo and may represent a promising phenotype-modulating tool for future therapeutic avenues.


Despite our growing understanding of the pathophysiology of burn wounds and the evolution of techniques and practices to manage infections, sepsis remains a significant medical concern for burn patients. P. aeruginosa continues to be a leader among all causes of bacteremic infections due to its tendency to cause complications in immunocompromised patients and its ubiquitous presence in the hospital setting. With the unforgiving emergence of multidrug-resistant strains, it is critical that alternative strategies to control or prevent septic infections in burn patients be developed in parallel with novel antimicrobial agents. In this study, we observed that administration of l-Arg significantly reduced bacterial spread and sepsis in burned mice infected with P. aeruginosa. Given the safety of l-Arg in high doses and its potential wound-healing benefits, this conditionally essential amino acid may represent a useful tool to modulate bacterial behavior in vivo and prevent sepsis in burn patients.


Nosocomial burn wound infections are responsible for up to 75% of deaths in thermally injured patients, and sepsis, secondary to infection, is the primary predictor of mortality (1,3). Mortality rates due to Gram-negative sepsis are over 60%, and the opportunistic pathogen Pseudomonas aeruginosa has the highest mortality rate among all causes of bacteremia (4). P. aeruginosa is equipped with a battery of virulence factors that help facilitate colonization of the burn wound and translocation through the vasculature and into the bloodstream (5,7); however, it is still unclear what instigates this rapid transition into the bloodstream.

The unchecked propagation and spread of P. aeruginosa are largely the consequence of impaired immunity. The host immune response that follows severe thermal trauma is a dichotomy of pro- and anti-inflammatory phases that results in a general state of immune dysfunction in burn patients. The early postburn cytokine response is largely characterized by the production of proinflammatory cytokines interleukin-1 (IL-1), IL-6, tumor necrosis factor alpha (TNF-α), and prostaglandin E2 (PGE2), causing massive inflammation that can transition to severe inflammatory response syndrome, ultimately resulting in shock and end organ failure (7, 8). The late postburn phase is dominated by the production of the anti-inflammatory cytokines IL-10 and IL-4 to compensate for the initial proinflammatory response (7, 9,11). If the burn covers more than 30% total body surface area (TBSA), the anti-inflammatory response can be so dramatic that the patient becomes severely immunocompromised, stemming from the activation of suppressor cell phenotypes, including CD4+ CD25+ regulatory T cells and a subset of immunoregulatory cells termed myeloid-derived suppressor cells (MDSCs) (12,16).

MDSCs can suppress both adaptive and innate immune responses in part by sequestering critical substrates necessary for T cell activation and proliferation. For example, MDSCs can respond to high levels of inflammation by increasing production of arginase I (ArgI), which subsequently depletes the environment of available arginine, thus reducing protein synthesis (17). Limited availability of arginine results in T cells being arrested in the G0-G1 phase of the cell cycle, preventing effective activation and proliferation and crippling the immune system from an adaptive defense standpoint (18).

Furthermore, severe burn trauma causes devascularization of the wound environment, which prevents neutrophils and other innate effector cells from migrating into the wound and clearing the bacterial infection. The avascular state of the burn wound results in a decreased supply of oxygen and other essential nutrients to the damaged tissue, which can lead to ischemia (19). Despite these limitations, P. aeruginosa can flourish within the burn wound and aggressively disseminate through the surrounding tissue and into the bloodstream. Reports have indicated that the availability of key amino acids, especially arginine, can influence the lifestyle and activity of P. aeruginosa within the cystic fibrosis (CF) lung environment by acting as an environmental cue (20, 21). In this study, we investigated the impact of arginine availability in a thermally injured mouse model of infection to assess whether limited access to this substrate influences the behavior of P. aeruginosa pathogenesis in burn wound infections.


Depleted arginine levels are associated with concentrated MDSC recruitment at the burn wound.

Previous studies have demonstrated a role for arginine in modulating P. aeruginosa behavior, including aspects of motility, which can subsequently influence P. aeruginosa virulence (20). Therefore, we measured the concentration of l-Arg in uninfected wounds of thermally injured mice and compared it to the concentration of l-Arg in nonburned tissue. P. aeruginosa can be detected in the bloodstream as early as 24 h after burn injury and infection; therefore, any significant change in arginine levels that would incur an effect on P. aeruginosa pathogenesis would occur at or before this time point. To our surprise, we observed that thermal insult alone caused an ~80% decrease (P < 0.001) in l-Arg levels by 24 h postburn, compared to the basal levels of l-Arg in nonburned tissue (Fig. 1A). Levels of arginase, the host enzyme that converts arginine to ornithine and urea, within these uninfected wounds increased ~30% (P < 0.01) as a result of burn injury, which could in part explain the reduction in l-Arg in these tissues (Fig. 1B).

Depleted arginine levels are associated with MDSC recruitment. Tissue from mice that received thermal insult (with or without infection) was harvested 24 h post-burn injury. (A) l-Arg concentrations were significantly reduced in burned mice (with ...

As P. aeruginosa is capable of metabolizing arginine to generate ATP under anaerobic conditions (22, 23), we next investigated how the presence of P. aeruginosa impacted the levels of arginine and arginase in thermally injured tissues. Our results revealed that infection of burn wounds with P. aeruginosa did not significantly alter the levels of arginine (Fig. 1A), although the levels of arginase were slightly elevated (Fig. 1B). Collectively, these data indicate that whether infected or uninfected, thermally injured tissue possesses significantly less arginine and significantly more arginase than uninjured tissue (Fig. 1).

As MDSCs are well known to produce arginase I in response to inflammation, we hypothesized that these cells are responsible for the high levels of arginase, and subsequently low levels of arginine, in thermally injured tissue (17, 18). While some MDSCs are known to be present in thermally injured tissue (16), it is unclear whether MDSCs are generally recruited to the inflamed tissue or if MDSCs exhibit a propensity to accumulate at the wound margin. To visualize the recruitment and distribution of MDSCs to uninfected burn wounds, we performed immunofluorescence microscopy on intact tissue immediately adjacent to the burn wound. Differentiation of MDSCs from other lymphocytes was accomplished by probing with two fluorophore-conjugated antibodies specific for the cell surface markers Gr-1 and CD11b, which are uniquely coexpressed on MDSCs. We observed a substantial number of Gr-1+ CD11b+ cells recruited to the tissue bordering the wound by 24 h post-thermal insult, and the distribution of MDSCs was heavily concentrated at the wound margin (Fig. 1C; see Fig. S1 in the supplemental material). No MDSCs were observed in tissue from nonburned mice (Fig. 1D; Fig. S1), reinforcing the tenet that these cells are only recruited to environments associated with high levels of proinflammatory cytokines. Taken together, these data indicate that MDSCs are recruited to thermally injured tissue and suggest that this is the likely mechanism of arginine depletion in burn wounds.



MDSC recruitment in thermally injured mice. Tissue was harvested from burn-only mice 24 h post-thermal insult or nonburned mice. Tissue samples were prepared for direct immunofluorescence microscopy with FITC-labeled anti-CD11b (green) and PE-labeled anti-Gr-1 antibodies (red). Host cell nuclei were counterstained with DAPI (blue). A large number of MDSCs coexpressing both CD11b and Gr-1 are recruited to the burned tissue-intact tissue interface. No MDSCs were observed in the tissue from the dorsum of nonburned mice. Sections were visualized via a Nikon Plan Fluor 20×/0.75, 40×/1.30 oil, and 100×/1.30 oil objectives. White size bars represent 50 µm. Red size bars represent 20 µm. Download FIG S1, PDF file, 0.3 MB.

Copyright © 2017 Everett et al.
This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

P. aeruginosa swimming motility is reduced by l-Arg.

We next set out to determine the impact of reduced arginine levels on P. aeruginosa physiology during burn wound infection. Of course, arginine is critical for protein synthesis in all organisms; however, in P. aeruginosa amino acids often serve as cues that regulate numerous phenotypes, including motility (20). In addition, it is well established that flagella are crucial for P. aeruginosa to enter the bloodstream and cause sepsis in thermally injured mice (24, 25); the 50% lethal dose (LD50) of nonflagellated P. aeruginosa mutants can be as much as 105 times greater than that of the wild-type strain in thermally injured mice. To test whether arginine levels impacted P. aeruginosa motility, we compared the swimming motilities of P. aeruginosa cells when grown on standard swimming plates supplemented with various concentrations of l-Arg (100, 250, 500, and 750 mM) (Fig. 2A). These concentrations fall within the range of l-Arg that have been administered topically to patients (26, 27). P. aeruginosa exhibited a small, but significant, increase in swimming motility when the medium was supplemented with 100 mM l-Arg; however, at higher concentrations, swimming motility was significantly reduced (Fig. 2A). To further test the impact of l-Arg on P. aeruginosa motility, we examined P. aeruginosa chemotaxis toward l-Arg using a diffusion-based microfluidic device (28). Analogous to previous reports evaluating P. aeruginosa chemotaxis, P. aeruginosa demonstrated a very robust chemotactic response toward l-Arg; however, the P. aeruginosa response toward l-Arg was nearly double in magnitude at every time point evaluated compared to that of l-Ser, a commonly used P. aeruginosa chemoattractant (29, 30) (Fig. 2B). Collectively, these data suggest that the reduced arginine levels in burns could trigger a response in swimming motility as a means for P. aeruginosa to seek out arginine via chemotaxis.

l-Arg is a potent chemoattractant for P. aeruginosa but reduces swimming motility at high concentrations. (A) Standard tryptone swim plates were supplemented with the indicated concentration of l-Arg. PAO1 swimming motility was significantly increased ...

l-Arg supplementation reduces P. aeruginosa spread and sepsis in thermally injured mice.

Based on the low levels of arginine present in burn wounds and our observation that low arginine levels trigger P. aeruginosa motility, we hypothesized that addition of l-Arg to the burn wound might attenuate the spread of P. aeruginosa in burned mice. To test this, we inoculated burned mice with P. aeruginosa cells mixed with either phosphate-buffered saline (PBS) or 0.125 g/ml l-Arg. This concentration of arginine equates to approximately 600 mM l-Arg HCl in each bolus injection or 1 g/kg of body weight per mouse and was previously shown to be safe for topical application in both rodents and humans (26, 31). In control mice (PBS treated), P. aeruginosa colonized and spread rapidly through the burn wound from the inoculation site to the perimeter of the wound by 18 h postburn and postinfection (Fig. 3A); however, addition of l-Arg resulted in slightly fewer P. aeruginosa cells at the inoculation site and over a 10,000-fold decrease in P. aeruginosa at the distal wound site. This response was magnified at later time points in infection when virtually no P. aeruginosa cells were found at the distal wound site in the l-Arg-treated group compared to 108 cells found in PBS-treated mice (Fig. 3B). It is curious that bacteria in the wild-type group treated with l-Arg were able to spread to the distal site at 18 h but were not recoverable from the same site at 36 h; however, the two time points represent two different animal groups, and the inherent variability associated with in vivo models may partially account for this. Additionally, systemic spread of P. aeruginosa to the spleen was reduced over 100-fold by the addition of l-Arg (Fig. 3B).

l-Arg supplementation reduced P. aeruginosa spread and mortality in thermally injured mice. Two groups of mice received third degree scald burns and were then inoculated with approximately 102 CFU of the PAO1 (Wt) or flgK mutant combined ...

For comparison, we also tested an avirulent P. aeruginosa flgK mutant that is defective in flagellum production and, subsequently, swimming motility. Because of this defect, the flgK mutant is unable to efficiently spread throughout the burn wound or cause sepsis, yet is still able to grow within the wound. We saw that l-Arg treatment does not significantly affect P. aeruginosa growth in the burn wound as there was no significant difference in bacterial loads at any sites between the PBS- or l-Arg-treated flgK mutant groups. Interestingly, the flgK mutant was able to reach the distal site at 36 h sans swimming motility. This is likely attributed to the fact that P. aeruginosa can facilitate other modes of motility beyond swimming (e.g., twitching). However, these other modes of motility are not as efficient as swimming, and it subsequently takes a much longer time for P. aeruginosa to disseminate when it lacks the ability to swim. The flgK mutant is also completely attenuated in burned mice, whereas a pil mutant, which is unable to twitch, remains fully virulent and causes a lethal infection in burned mice (unpublished results). Therefore, we concluded that the reduced spread of P. aeruginosa observed in the l-Arg-treated wild-type group is attributed to decreased swimming motility and not growth inhibition.

Based on these data, we hypothesized that l-Arg application to P. aeruginosa burn wound infections would increase animal survival. To test this hypothesis, we treated burned mice with l-Arg in the form of a bolus injection mixed with the bacterial inoculum followed by a second injection of either l-Arg or PBS directly into the burn wound at 24 h postinfection. Control mice (PBS treated) exhibited signs of sepsis by 48 h, and all became moribund by 72 h postburn and postinfection (Fig. 3C); however, a significant number of l-Arg-treated mice exhibited minimal signs of sickness and remained healthy up to the end of the study (Fig. 3C). It is worth noting that supplementation of l-Ser at the same concentration in burned and infected mice did not impart any advantage in terms of survival or animal health, suggesting that the effect of l-Arg has some degree of specificity (Fig. 3C). These results suggest that arginine may represent a useful tool to slow or prevent the dissemination of P. aeruginosa infection to the bloodstream in severely burned patients when applied locally into the burn wound.


Here we report that administration of l-Arg hydrochloride significantly prolonged animal survival and reduced P. aeruginosa sepsis in burned mice. To our knowledge, this is the first demonstration that l-Arg can benefit animal survival by effectively reducing the systemic spread of this common nosocomial pathogen. The mechanism of this response is likely mediated by reversing the paucity of available arginine in the burn wound caused by exaggerated arginase production by MDSCs, which subsequently reduces P. aeruginosa motility. l-Arg is already frequently used as a dietary supplement to resuscitate burned individuals with cutaneous and lung injuries (32,36). Therefore, the development of an arginine-based topical treatment has the potential to both aid in patient recovery as well as reduce the spread of aggressive multidrug-resistant bacterial strains, like those of P. aeruginosa.

Previous reports have demonstrated that l-Arg reduced P. aeruginosa swarming motility and enhanced biofilm formation, suggesting that arginine represents an environmental cue that influences P. aeruginosa to favor a sessile, biofilm-forming lifestyle over a more active, motile one (20). However, up until now, this hypothesis had not previously been tested in vivo. Our data demonstrated that arginine potently inhibited P. aeruginosa swimming motility, and this likely resulted in the attenuation of sepsis in vivo. Although the concentrations of arginine evaluated here greatly exceed the basal levels of arginine in nonburned tissue, these concentrations are therapeutically administered in humans and have been proven to be safe. Furthermore, this is the first demonstration, to our knowledge, that these concentrations of arginine have a positive effect in vivo by negating the rapid dissemination of P. aeruginosa into the bloodstream via reduced swimming motility.

Given the strong chemotactic response P. aeruginosa displayed toward modest concentrations of l-Arg, it is possible that the aggressive dissemination of P. aeruginosa in burn wounds is driven by its need for this substrate when arginase production is elevated following MDSC recruitment. This finding would suggest a new role for MDSCs during infection: that the consequence of MDSC recruitment is not simply restricted to the classical obstruction of efficient activation of T cells and antimicrobial production, but that they also play a significant role in modulating bacterial behavior by limiting the availability of key nutrients, such as arginine, in the burn wound environment. Pharmacological options are available that can significantly decrease the number of MDSCs in vivo (37, 38); however, the negative physiological consequences associated with the use of chemotherapeutic drugs render them nonideal treatment options in burn patients. In contrast, the safety of concentrated doses and the potential wound-healing benefits of arginine make it an attractive alternative to counter the effects of exaggerated arginase production by MDSCs and subsequently deter P. aeruginosa motility into the surrounding tissue and bloodstream.

We are now in an era of very limited therapeutic options for infections caused by multidrug-resistant bacteria such as P. aeruginosa, and finding alternative treatments is imperative. Our data suggest that in addition to bactericidal agents, vaccines, and antivirulence approaches, modulating bacterial phenotypes by altering the infection microenvironment may be a promising method to halt sepsis. The effectiveness we observed here with therapeutic concentrations of arginine could potentially circumvent the complications associated with active and passive immunization strategies while still lowering the incidence of sepsis. Conventional antibiotics or other means of antimicrobial treatment will likely still be required to effectively clear the infection, but the use of arginine to modulate P. aeruginosa behavior and stymie systemic spread may prove to be a valuable component in future combinatorial therapies.


Bacterial strains and growth conditions.

The P. aeruginosa strain PAO1 (39), PAO1 containing the green fluorescent protein (GFP)-expressing plasmid pMRP9-1 (40), and the PA14 flgK transposon mutant (41) have been described previously (40). For general growth of P. aeruginosa, strains were grown aerobically in Luria-Bertani (LB) broth at 37°C, with shaking at 200 rpm, unless otherwise noted. PAO1-GFP and flgK were grown aerobically at 37°C in LB broth supplemented with 300 μg/ml carbenicillin or 20 µg/ml tetracycline, respectively.

Thermally injured mouse model of infection.

The thermally injured mouse model of infection was adapted from the burned-mouse model described by Stieritz and Holder (42,44). Burn experiments were conducted in adult female Swiss Webster mice (Charles River Laboratories, Inc.) weighing between 20 and 25 g. Mice were anesthetized by intraperitoneal injection of 0.4 ml of 5% sodium pentobarbital (Nembutal; Oak Pharmaceuticals, Inc.) at 5 mg/ml before their backs were shaved, and the hair was cleanly removed with a depilatory agent. Thermal injury was induced by placing an exposed area of the shaved skin (approximately 15% total body surface area) in a 90°C water bath for 10 s. This scald injury is nonlethal but induces a third-degree (full-thickness) burn. Where specified, nonburned mice served as controls, and their backs were shaved and treated with a depilatory agent in parallel with thermally injured mice before they were euthanized prior to collection of tissue. For survival experiments, mice were monitored for 7 days postburn and/or infection. At the specified end time point or in the event mice became moribund, mice were euthanized by intracardiac injection of 200 μl (390 mg/ml) Fatal-Plus (Vortech Pharmaceuticals, Ltd.). Animals were treated humanely and in accordance with protocol 96020 approved by the Institutional Animal Care and Use Committee at Texas Tech University Health Sciences Center in Lubbock, TX.

Preparation of P. aeruginosa inoculum for challenge in thermally injured mice.

P. aeruginosa inocula for challenge in thermally injured mice were prepared as previously described (43, 44). For treatment experiments, approximately 102 CFU PAO1 in 100 µl 1× PBS were combined with 200 µl of 0.125 g/ml of either l-Arg (l-Arg hydrochloride; Fisher BioReagents) or l-Ser (Fisher BioReagents) prepared in 1× PBS (pH 7.1 to 7.2) before inoculation into burned mice. Mice received the mixture of PAO1 cells plus l-Arg as a 300-µl bolus injection directly into the burn wound following thermal insult. Control mice received a 300-µl bolus injection of a mixture of PAO1 plus 1× PBS (approximately 102 CFU of PAO1 combined with 200 µl 1× PBS) directly into the burn wound following thermal insult. Mixtures containing PAO1 cells plus l-Arg and PAO1 plus 1× PBS were prepared immediately prior to inoculation.

Immunofluorescence imaging of MDSCs.

Immunofluorescence imaging of MDSC within burned and nonburned tissue was performed on frozen tissue sections. Briefly, tissue from thermally injured mice encompassing both the burn wound and the intact tissue bordering the burn was resized to approximately 1 cm by 0.5 cm and placed into a Tissue-Tek vinyl specimen Cryomold (Sakura Finetek) containing Cryomatrix optimum cutting temperature (OCT) compound (Thermo Fisher Scientific) and then placed into a freezer at −80°C to solidify before sectioning. Tissue from nonburned mice was resected from the center of the dorsum and prepared in parallel with burned tissue. Frozen OCT-embedded samples were sectioned using an OTF5000 cryostat (Bright Instrument Co., Ltd.) to a thickness of 4 to 6 µm and then directly transferred to Superfrost Plus microscope slides (Thermo Fisher Scientific) and stored at −80°C. Tissue samples were cut and oriented so that the burn wound-intact tissue interface could be best visualized. Tissue sections were incubated with fluorescein isothiocyanate (FITC)-labeled rat anti-mouse CD11b/Mac-1 antibody (Southern Biotech) (1:100 anti-CD11b, 1× PBS, 2% goat serum) and phycoerythrin (PE)-labeled rat anti-mouse Gr-1/Ly-6G antibody (Southern Biotech) (1:75 anti-Gr-1, 1× PBS, 2% goat serum). Each section was mounted with ProLong Gold antifade reagent (Molecular Probes) supplemented with DAPI (4′,6′-diamidino-2-phenylindole) to stain DNA. Mounted slides were visualized by epifluorescence microscopy with a Nikon Eclipse 80i microscope (Nikon), and images were captured with a Nikon DS-Fi1 camera (Nikon) and analyzed with the NIS Elements program (version 3.00 SP7; Nikon, Japan).

ELISA for measurement of l-Arg and arginase.

Mouse l-Arg and arginase I concentrations were measured in tissue homogenates via commercially available enzyme-linked immunosorbent assay (ELISA) kits (MBS2600680 and MBS745422; MyBioSource) as per the manufacturer’s instructions. Briefly, approximately 100 mg of tissue was resected from the center of the wound in burned mice at 24 h postinsult (with or without infection) or from the center of the dorsum in noninjured mice. Tissue samples were placed into Precellys 2.8-mm steel bead kit (Peqlab) homogenizing tubes filled with 1 ml Pierce radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher Scientific) and then processed using a dedicated tissue homogenizer (Bertin Technologies). Homogenates were centrifuged, and the supernatants were collected from each sample. Aliquots of supernatants were then transferred to ELISA plates to measure l-Arg and arginase. Concentrations are normalized to the amount of tissue.

Swimming motility assay and l-Arg-supplemented plates.

The swimming motility assay was adapted from Deziel et al. (45) and conducted on standard tryptone agar plates. For swim plates supplemented with l-Arg, l-Arg HCl (Fisher BioReagents) was added to standard tryptone swim medium to attain the specified concentration and adjusted to pH 7.1 to 7.2 before agar was added and the complete medium was autoclaved. l-Arg-supplemented swim plates were allowed to dry overnight at room temperature before inoculation.

Chemotaxis in a microfluidic chip.

Evaluation of swimming-mediated chemotaxis was carried out in an agarose gel-based two-layer microfluidic device described previously (28) with the following modifications. PAO1-GFP cells were cultured in standard LB supplemented with carbenicillin to an optical density at 600 nm (OD600) of 1.0. Cells were harvested by centrifugation (300 × g for 4 min), washed in chemotaxis buffer (CB) (1× PBS supplemented with 5 mM MgSO4 and 15 µM EDTA), and then readjusted in CB to an OD600 of 0.2. CB was added to the source wells, and CB-washed PAO1-GFP cells were added to the sink wells. The cell density profile in the observation channel was incubated for 30 min, at which time CB in the source well was removed and replaced with 30 µl of the indicated chemoattractant (1 mM l-Arg in CB), positive control (1 mM l-Ser in CB), or CB alone as the negative control. Fluorescent images were acquired at 10-min intervals for 1 h. Cell density was measured by the fluorescence intensity within the region of interest (ROI) and was normalized to the background.

Processing of tissue to determine local and systemic bacterial spread.

For experiments where bacterial spread was evaluated in burned mice, animals were euthanized at 18 or 36 h postinfection, and approximately 80 to 100 mg tissue was harvested from multiple sites, including tissue from the inoculation (center of wound) and distal/periphery (~3 cm from inoculation site) sites, as well as spleens where noted. Harvested tissue was then placed in Precellys 2.8-mm steel bead kit homogenizing tubes filled with 1× PBS and homogenized using a dedicated tissue homogenizer. Burn wound and spleen homogenates were then serially diluted (10-fold), plated on Pseudomonas isolation agar, and incubated overnight at 37°C before CFU were counted and the bacterial load (CFU per gram of tissue) was calculated for each sample.


This work was supported in part by grant AI105763 (K.P.R.) from the National Institute of Allergy and Infectious Diseases and grant W911NF-13-1-0199 (M.W. and K.P.R.) from the Army Research Office.


Citation Everett J, Turner K, Cai Q, Gordon V, Whiteley M, Rumbaugh K. 2017. Arginine is a critical substrate for the pathogenesis of Pseudomonas aeruginosa in burn wound infections. mBio 8:e02160-16.


1. Azzopardi EA, Azzopardi SM, Boyce DE, Dickson WA 2011. Emerging Gram-negative infections in burn wounds. J Burn Care Res 32:570–576. doi:.10.1097/BCR.0b013e31822ac7e6 [PubMed] [Cross Ref]
2. Ansermino M, Hemsley C 2004. Intensive care management and control of infection. BMJ 329:220–223. doi:.10.1136/bmj.329.7459.220 [PMC free article] [PubMed] [Cross Ref]
3. Mason AD Jr, McManus AT, Pruitt BA Jr. 1986. Association of burn mortality and bacteremia. A 25-year review. Arch Surg 121:1027–1031. doi:.10.1001/archsurg.1986.01400090057009 [PubMed] [Cross Ref]
4. Young LS. 1990. Gram-negative sepsis, p 611–636. In Mandell GL, Douglas RG Jr, Bennet JE (ed), Principles and practice of infectious diseases, 3rd ed. Churchill Livingstone, New York, NY.
5. Lyczak JB, Cannon CL, Pier GB 2000. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2:1051–1060. doi:.10.1016/S1286-4579(00)01259-4 [PubMed] [Cross Ref]
6. Branski LK, Al-Mousawi A, Rivero H, Jeschke MG, Sanford AP, Herndon DN 2009. Emerging infections in burns. Surg Infect (Larchmt) 10:389–397. doi:.10.1089/sur.2009.024 [PMC free article] [PubMed] [Cross Ref]
7. Church D, Elsayed S, Reid O, Winston B, Lindsay R 2006. Burn wound infections. Clin Microbiol Rev 19:403–434. doi:.10.1128/CMR.19.2.403-434.2006 [PMC free article] [PubMed] [Cross Ref]
8. Bone RC. 1996. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 125:680–687. doi:.10.7326/0003-4819-125-8-199610150-00009 [PubMed] [Cross Ref]
9. Gosain A, Gamelli RL 2005. A primer in cytokines. J Burn Care Rehab 26:7–12. doi:.10.1097/01.BCR.0000150214.72984.44 [PubMed] [Cross Ref]
10. Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA 1989. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci U S A 86:3803–3807. doi:.10.1073/pnas.86.10.3803 [PubMed] [Cross Ref]
11. Oswald IP, Wynn TA, Sher A, James SL 1992. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation. Proc Natl Acad Sci U S A 89:8676–8680. doi:.10.1073/pnas.89.18.8676 [PubMed] [Cross Ref]
12. Weber J, McManus A, Nursing Committee of the International Society for Burn Injuries 2004. Infection control in burn patients. Burns 30:A16–A24. doi:.10.1016/j.burns.2004.08.003 [PubMed] [Cross Ref]
13. MacConmara MP, Maung AA, Fujimi S, McKenna AM, Delisle A, Lapchak PH, Rogers S, Lederer JA, Mannick JA 2006. Increased CD4+ CD25+ T regulatory cell activity in trauma patients depresses protective Th1 immunity. Ann Surg 244:514–523. doi:.10.1097/01.sla.0000239031.06906.1f [PubMed] [Cross Ref]
14. Ni Choileain N, MacConmara M, Zang Y, Murphy TJ, Mannick JA, Lederer JA 2006. Enhanced regulatory T cell activity is an element of the host response to injury. J Immunol 176:225–236. doi:.10.4049/jimmunol.176.1.225 [PubMed] [Cross Ref]
15. Adib-Conquy M, Cavaillon JM 2009. Compensatory anti-inflammatory response syndrome. Thromb Haemost 101:36–47. doi:.10.1160/TH08-07-0421 [PubMed] [Cross Ref]
16. Kobayashi M, Yoshida T, Takeuchi D, Jones VC, Shigematsu K, Herndon DN, Suzuki F 2008. Gr-1(+)CD11b(+) cells as an accelerator of sepsis stemming from Pseudomonas aeruginosa wound infection in thermally injured mice. J Leukoc Biol 83:1354–1362. doi:.10.1189/jlb.0807541 [PubMed] [Cross Ref]
17. Bronte V, Zanovello P 2005. Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 5:641–654. doi:.10.1038/nri1668 [PubMed] [Cross Ref]
18. Rodriguez PC, Quiceno DG, Ochoa AC 2007. l-Arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109:1568–1573. doi:.10.1182/blood-2006-06-031856 [PubMed] [Cross Ref]
19. Xing D, Liu L, Marti GP, Zhang X, Reinblatt M, Milner SM, Harmon JW 2011. Hypoxia and hypoxia-inducible factor in the burn wound. Wound Repair Regen 19:205–213. doi:.10.1111/j.1524-475X.2010.00656.x [PMC free article] [PubMed] [Cross Ref]
20. Bernier SP, Ha DG, Khan W, Merritt JH, O’Toole GA 2011. Modulation of Pseudomonas aeruginosa surface-associated group behaviors by individual amino acids through c-di-GMP signaling. Res Microbiol 162:680–688. doi:.10.1016/j.resmic.2011.04.014 [PMC free article] [PubMed] [Cross Ref]
21. Palmer KL, Mashburn LM, Singh PK, Whiteley M 2005. Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology. J Bacteriol 187:5267–5277. doi:.10.1128/JB.187.15.5267-5277.2005 [PMC free article] [PubMed] [Cross Ref]
22. Vander Wauven C, Piérard A, Kley-Raymann M, Haas D 1984. Pseudomonas aeruginosa mutants affected in anaerobic growth on arginine: evidence for a four-gene cluster encoding the arginine deiminase pathway. J Bacteriol 160:928–934. [PMC free article] [PubMed]
23. Lüthi E, Baur H, Gamper M, Brunner F, Villeval D, Mercenier A, Haas D 1990. The arc operon for anaerobic arginine catabolism in Pseudomonas aeruginosa contains an additional gene, arcD, encoding a membrane protein. Gene 87:37–43. doi:.10.1016/0378-1119(90)90493-B [PubMed] [Cross Ref]
24. Sato H, Okinaga K, Saito H 1988. Role of pili in the pathogenesis of Pseudomonas aeruginosa burn infection. Microbiol Immunol 32:131–139. doi:.10.1111/j.1348-0421.1988.tb01372.x [PubMed] [Cross Ref]
25. Drake D, Montie TC 1988. Flagella, motility and invasive virulence of Pseudomonas aeruginosa. J Gen Microbiol 134:43–52. doi:.10.1099/00221287-134-1-43 [PubMed] [Cross Ref]
26. Gosselink MP, Darby M, Zimmerman DD, Gruss HJ, Schouten WR 2005. Treatment of chronic anal fissure by application of l-arginine gel: a phase II study in 15 patients. Dis Colon Rectum 48:832–837. doi:.10.1007/s10350-004-0858-7 [PubMed] [Cross Ref]
27. Cassone Faldetta M, Laurenti O, Desideri G, Bravi MC, De Luca O, Marinucci MC, De Mattia G, Ferri C 2002. l-Arginine infusion decreases plasma total homocysteine concentrations through increased nitric oxide production and decreased oxidative status in type II diabetic patients. Diabetologia 45:1120–1127. doi:.10.1007/s00125-002-0854-1 [PubMed] [Cross Ref]
28. Si G, Yang W, Bi S, Luo C, Ouyang Q 2012. A parallel diffusion-based microfluidic device for bacterial chemotaxis analysis. Lab Chip 12:1389–1394. doi:.10.1039/c2lc21219f [PubMed] [Cross Ref]
29. Nikata T, Sumida K, Kato J, Ohtake H 1992. Rapid method for analyzing bacterial behavioral responses to chemical stimuli. Appl Environ Microbiol 58:2250–2254. [PMC free article] [PubMed]
30. Moulton RC, Montie TC 1979. Chemotaxis by Pseudomonas aeruginosa. J Bacteriol 137:274–280. [PMC free article] [PubMed]
31. Zandifar A, Seifabadi S, Zandifar E, Beheshti SS, Aslani A, Javanmard SH 2015. Comparison of the effect of topical versus systemic l-arginine on wound healing in acute incisional diabetic rat model. J Res Med Sci 20:233–238. [PMC free article] [PubMed]
32. Murakami K, Enkhbaatar P, Yu YM, Traber LD, Cox RA, Hawkins HK, Tompkins RG, Herndon D, Traber DL 2007. l-Arginine attenuates acute lung injury after smoke inhalation and burn injury in sheep. Shock 28:477–483. doi:.10.1097/shk.0b013e31804a59bd [PubMed] [Cross Ref]
33. Yan H, Peng X, Huang Y, Zhao M, Li F, Wang P 2007. Effects of early enteral arginine supplementation on resuscitation of severe burn patients. Burns 33:179–184. doi:.10.1016/j.burns.2006.06.012 [PubMed] [Cross Ref]
34. Marin VB, Rodriguez-Osiac L, Schlessinger L, Villegas J, Lopez M, Castillo-Duran C 2006. Controlled study of enteral arginine supplementation in burned children: impact on immunologic and metabolic status. Nutrition 22:705–712. doi:.10.1016/j.nut.2006.03.009 [PubMed] [Cross Ref]
35. Ali S, Roberts PR 2006. Nutrients with immune-modulating effects: what role should they play in the intensive care unit? Curr Opin Anaesthesiol 19:132–139. doi:.10.1097/ [PubMed] [Cross Ref]
36. Appleton J. 2002. Arginine: clinical potential of a semi-essential amino acid. Altern Med Rev 7:512–522. [PubMed]
37. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM 2005. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11:6713–6721. doi:.10.1158/1078-0432.CCR-05-0883 [PubMed] [Cross Ref]
38. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F 2010. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70:3052–3061. doi:.10.1158/0008-5472.CAN-09-3690 [PubMed] [Cross Ref]
39. Holloway BW, Krishnapillai V, Morgan AF 1979. Chromosomal genetics of Pseudomonas. Microbiol Rev 43:73–102. [PMC free article] [PubMed]
40. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP 1998. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280:295–298. doi:.10.1126/science.280.5361.295 [PubMed] [Cross Ref]
41. O’Toole GA, Kolter R 1998. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 30:295–304. doi:.10.1046/j.1365-2958.1998.01062.x [PubMed] [Cross Ref]
42. Stieritz DD, Holder IA 1975. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. J Infect Dis 131:688–691. doi:.10.1093/infdis/131.6.688 [PubMed] [Cross Ref]
43. Rumbaugh KP, Griswold JA, Hamood AN 1999. Contribution of the regulatory gene lasR to the pathogenesis of Pseudomonas aeruginosa infection of burned mice. J Burn Care Rehab 20:42–49. doi:.10.1097/00004630-199901001-00008 [PubMed] [Cross Ref]
44. Schaber JA, Triffo WJ, Suh SJ, Oliver JW, Hastert MC, Griswold JA, Auer M, Hamood AN, Rumbaugh KP 2007. Pseudomonas aeruginosa forms biofilms in acute infection independent of cell-to-cell signaling. Infect Immun 75:3715–3721. doi:.10.1128/IAI.00586-07 [PMC free article] [PubMed] [Cross Ref]
45. Déziel E, Comeau Y, Villemur R 2001. Initiation of biofilm formation by Pseudomonas aeruginosa 57RP correlates with emergence of hyperpiliated and highly adherent phenotypic variants deficient in swimming, swarming, and twitching motilities. J Bacteriol 183:1195–1204. doi:.10.1128/JB.183.4.1195-1204.2001 [PMC free article] [PubMed] [Cross Ref]

Articles from mBio are provided here courtesy of American Society for Microbiology (ASM)